Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Intellia Therapeutics to post earnings of ($1.37) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same period in the prior year, the company earned ($1.40) earnings per share. The firm's quarterly revenue was down 48.5% on a year-over-year basis. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Trading Up 1.9 %

NTLA stock traded up $0.29 during trading hours on Tuesday, hitting $15.43. 1,902,083 shares of the stock traded hands, compared to its average volume of 1,640,403. The stock has a 50-day simple moving average of $19.55 and a 200 day simple moving average of $22.34. Intellia Therapeutics has a one year low of $13.95 and a one year high of $34.87. The company has a market cap of $1.57 billion, a P/E ratio of -2.82 and a beta of 1.81.

Analyst Ratings Changes

Several brokerages recently weighed in on NTLA. The Goldman Sachs Group decreased their target price on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a research report on Friday, August 9th. Robert W. Baird decreased their price target on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, Chardan Capital decreased their price objective on Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating for the company in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $59.13.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.20% of the stock is currently owned by corporate insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.